AU2007225477A1 - A new crystalline form G of (5S) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (I) and intermediates thereof. - Google Patents

A new crystalline form G of (5S) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (I) and intermediates thereof. Download PDF

Info

Publication number
AU2007225477A1
AU2007225477A1 AU2007225477A AU2007225477A AU2007225477A1 AU 2007225477 A1 AU2007225477 A1 AU 2007225477A1 AU 2007225477 A AU2007225477 A AU 2007225477A AU 2007225477 A AU2007225477 A AU 2007225477A AU 2007225477 A1 AU2007225477 A1 AU 2007225477A1
Authority
AU
Australia
Prior art keywords
methyl
imidazolidine
dione
chloro
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007225477A
Other languages
English (en)
Inventor
Neil Barnwell
Lars-Erik Briggner
Andrea Cole
Anders Eriksson
Jacob Perkins
Luis-Manuel Vaz
Andrew Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38509897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007225477(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2007225477A1 publication Critical patent/AU2007225477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007225477A 2006-03-16 2007-03-15 A new crystalline form G of (5S) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (I) and intermediates thereof. Abandoned AU2007225477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78297906P 2006-03-16 2006-03-16
US60/782,979 2006-03-16
PCT/SE2007/000256 WO2007106022A2 (en) 2006-03-16 2007-03-15 A new crystalline form g of (5s) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (i) and intermediates thereof.

Publications (1)

Publication Number Publication Date
AU2007225477A1 true AU2007225477A1 (en) 2007-09-20

Family

ID=38509897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007225477A Abandoned AU2007225477A1 (en) 2006-03-16 2007-03-15 A new crystalline form G of (5S) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (I) and intermediates thereof.

Country Status (16)

Country Link
US (1) US20090221640A1 (enExample)
EP (1) EP2064202A4 (enExample)
JP (1) JP2009531313A (enExample)
KR (1) KR20090008229A (enExample)
CN (1) CN101448819A (enExample)
AR (1) AR059913A1 (enExample)
AU (1) AU2007225477A1 (enExample)
BR (1) BRPI0709579A2 (enExample)
CA (1) CA2644345A1 (enExample)
CL (1) CL2007000680A1 (enExample)
IL (1) IL193670A0 (enExample)
MX (1) MX2008011641A (enExample)
NO (1) NO20084282L (enExample)
TW (1) TW200800954A (enExample)
UY (1) UY30214A1 (enExample)
WO (1) WO2007106022A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
JP5838226B2 (ja) 2011-01-13 2016-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート誘導体の製造方法
EP2797881B1 (en) 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2014178433A1 (ja) 2013-05-02 2014-11-06 株式会社エーピーアイ コーポレーション α－置換システインもしくはその塩又はα－置換システイン合成中間体の製造方法
CN116033902A (zh) 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
CN117820178A (zh) * 2023-12-26 2024-04-05 山东泰和科技股份有限公司 一种d,l-蛋氨酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6172762A (ja) * 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
GB8618559D0 (en) * 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) * 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) * 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
NL9201230A (nl) * 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
TW514634B (en) * 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
CN1509275A (zh) * 2001-03-15 2004-06-30 金属蛋白酶抑制剂
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CN1665803A (zh) * 2002-04-30 2005-09-07 特瓦药厂有限公司 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法
CN1665504A (zh) * 2002-05-10 2005-09-07 特瓦制药工业有限公司 新晶型的加替沙星
KR20050010826A (ko) * 2002-06-05 2005-01-28 가부시키가이샤 가네카 광학 활성 α-메틸시스테인 유도체의 제조 방법
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine

Also Published As

Publication number Publication date
AR059913A1 (es) 2008-05-07
EP2064202A2 (en) 2009-06-03
NO20084282L (no) 2008-10-13
TW200800954A (en) 2008-01-01
EP2064202A4 (en) 2011-01-12
CA2644345A1 (en) 2007-09-20
CL2007000680A1 (es) 2008-02-08
KR20090008229A (ko) 2009-01-21
WO2007106022A2 (en) 2007-09-20
JP2009531313A (ja) 2009-09-03
BRPI0709579A2 (pt) 2011-07-19
WO2007106022A3 (en) 2007-11-01
UY30214A1 (es) 2007-10-31
MX2008011641A (es) 2008-09-22
US20090221640A1 (en) 2009-09-03
CN101448819A (zh) 2009-06-03
IL193670A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
US20090221640A1 (en) Novel Crystal Modifications
KR100853049B1 (ko) 산화질소 신타제 억제제 포스페이트염
EP2649060B1 (en) Process for the preparation of benzimidazole derivatives and its salts
US9643927B1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
CN1121387C (zh) 3,4,4－三取代的哌啶基－n－烷基羧酸盐类化合物的制备及中间体
US10550087B2 (en) Process for the preparation of kinase inhibitors and intermediates thereof
HUT74103A (en) Aroyl-piperidine derivative
JP2011509916A (ja) チアゾリジン誘導体およびその製造方法
SK18052000A3 (sk) Amidínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
CZ293099B6 (cs) Amidinová sloučenina s inhibičním účinkem na syntázu oxidu dusnatého, způsob výroby a farmaceutický prostředek
US20100093816A1 (en) salt
JP6370316B2 (ja) エナンチオマー濃縮された３−アミノピペリジンの調製のためのプロセス
KR20000005505A (ko) 피페리딘 및 피롤리딘
CN1610674A (zh) 2－氨基－二氢噻唑衍生物及其作为诱导型no－合酶抑制剂的用途
WO2015032942A1 (en) N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
US12060345B2 (en) Process for preparing a phthalazinone derivative and intermediates thereof
WO2021106988A1 (ja) Ｇ９ａ阻害剤
EP4357335A1 (en) Azabicyclo[3.1.0]hexane compound
WO2023136942A1 (en) Synthetic intermediates and improved processes for preparing rock inhibitors
TW201329087A (zh) 胜肽脫甲醯酶抑制劑
HK1100442A (en) Butyrylcholinesterase selective inhibitors

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted